Ayurvedic treatment of Chronic Obstructive Pulmonary disease with oral administration of Shatyadi churna and Nebulization with Shirishadi Arka

Efficacy of oral Administration of Shatyadi Churna and Nebulization with Shirishadi Arka as Add-on in the Management of Chronic Obstructive Pulmonary Disease (Tamaka Shwasa) A Randomized Placebo Controlled clinical Trial - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/02/081104

Enrollment

Registered

2025-02-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J449- Chronic obstructive pulmonary disease, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients willing for trial and ready to give written consent. 2. Patients of age group 40-75 years. 3. Patients who have symptomatic stable COPD (diagnosis with postbronchodilator) 4. Patients getting conventional treatment as per allopathic standards. 5. GOLD grade I, II and III.

Exclusion criteria

Exclusion criteria: 1. Patients not willing for trial. 2. Age more than 75 years or less than 40 years. 3. Patients having bronchial asthma. 4. Patients not getting conventional treatment as per allopathic standards. 5. Patients who have a history of myocardial infarction, heart failure, acute ischemic coronary disease or severe cardiac arrhythmia requiring treatment within last 6 weeks 6. Patients with concomitant pulmonary disease, e.g., pulmonary tuberculosis or clinically significant bronchiectasis, sarcoidosis and interstitial lung disorder. 7. Patients with advanced Type II respiratory failure, GOLD grade IV (FEV1% less than 30% of predicted ). 8.Patient requiring long-term oxygen therapy (LTOT). 9.Patient suffering from major systemic illness necessitating long term treatment (RA ,malignancy). 10.Poorly controlled hypertension (BP greater than 180/100 mm of Hg) and diabetic patients (FBS greater than 150mg/dl). 11.Patients having end stage hepatic dysfunction (AST/ALT greater than 4 times of upper normal limit), or renal dysfunction (S.creatinine greater than 1.5mg/dl).

Design outcomes

Primary

Measure	Time frame
Improvement in FEV1, improvement in COPD Assessment Test (CAT) scoreTimepoint: 60 days	—

Secondary

Measure	Time frame
1. Improvement in signs & symptoms as per grading system 2. Improvement in rate of exacerbation 3. Improvement in FEV1/FVC 4. Improvement in PEFR 5. Improvement in SpO2 Timepoint: 60 days	—

Countries

India

Contacts

Public ContactKshitiz Koundal

Institute of Teaching and Research in Ayurveda Jamnagar

vyashetal1979@gmail.com9427941558

Outcome results